Join

Compare · FLAG vs GILD

FLAG vs GILD

Side-by-side comparison of First Light Acquisition Group Inc. (FLAG) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both FLAG and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • GILD is the larger of the two at $86.38B, about 305.6x FLAG ($282.6M).
  • Over the past year, FLAG is up 0.0% and GILD is up 22.6% - GILD leads by 22.6 points.
  • GILD has hit the wire 8 times in the past 4 weeks while FLAG has been quiet.
  • GILD has more recent analyst coverage (25 ratings vs 0 for FLAG).
PerformanceFLAG+0.00%GILD-6.57%
2026-01-29+0.00%2026-04-24
MetricFLAGGILD
Company
First Light Acquisition Group Inc.
Gilead Sciences Inc.
Price
$27.42+268.55%
$130.38-2.48%
Market cap
$282.6M
$86.38B
1M return
+0.00%
-5.67%
1Y return
+0.00%
+22.62%
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NYSE
NASDAQ
IPO
2021
1992
News (4w)
0
8
Recent ratings
0
25
FLAG

First Light Acquisition Group Inc.

First Light Acquisition Group, Inc. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is headquartered in Reston, Virginia.

GILD

Gilead Sciences Inc.

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.

Latest FLAG

Latest GILD